BTK and B-cell chronic lymphocytic leukemia: Similarly, a recent study from our group showed that two pathways downstream of the BCR are involved in inactivation of the kinase GSK3 in chronic lymphocytic leukemia (CLL) cells, resulting in a different capacity of SYK, BTK, and PI3Kδ inhibitors to reduce the expression of the antiapoptotic protein Mcl-1, which is negatively regulated by GSK3 [20].